Supplementary Online Content

Sargen MR, Cahoon EK, Lynch CF, Tucker MA, Goldstein AM, Engels EA. Sebaceous carcinoma incidence and survival among solid organ transplant recipients in the United States, 1987-2017. *JAMA Dermatol*. Published online November 4, 2020. doi:10.1001/jamadermatol.2020.3111

eTable. Univariate Incidence Rate Ratios for Sebaceous Carcinoma Risk Among Solid Organ Transplant Recipients

This supplementary material has been provided by the authors to give readers additional information about their work.

© 2020 American Medical Association. All rights reserved.

eTable 1. Univariate Incidence Rate Ratios for Sebaceous Carcinoma Risk Among Solid Organ Transplant Recipients

Characteristic	Observed cases	Incidence rate per 100,000 person-years	IRR (95% CI)[a]	P-value
Overall	102	5.90	-	-
Gender				<0.001
Female	19	2.81	Reference	
Male	83	7.90	2.81 (1.71-4.63)	
Race/ethnicity				0.001
Non-Hispanic white	80	7.15	Reference	
Non-Hispanic black	4	1.46	0.20 (0.07-0.56)	
Hispanic	13	5.35	0.75 (0.42-1.35)	
Asian or Pacific Islander	5	5.44	0.76 (0.31-1.88)	
Age at transplant, years				<0.001[b]
0-44	13	1.80	Reference	
45-54	31	6.77	3.77 (1.97-7.20)	
55-64	37	9.22	5.13 (2.73-9.65)	
≥65	21	14.5	8.05 (4.03-16.1)	
Transplanted organ				0.01
Kidney	59	5.87	Reference	
Liver	13	3.43	0.58 (0.32-1.06)	
Heart only	18	9.58	1.63 (0.96-2.77)	
Lung only	8	13.3	2.26 (1.08-4.73)	
Other/multiple	4	4.21	0.72 (0.26-1.98)	
Transplant number				0.25
First	91	5.75	Reference	
Second or later	11	8.29	1.44 (0.77-2.70)	
Calendar year of transplant				0.43[b]
1987-1994	13	5.62	Reference	
1995-2002	51	6.65	1.18 (0.64-2.18)	
2003-2010	34	5.38	0.96 (0.51-1.82)	
2011-2017	4	4.07	0.72 (0.24-2.22)	
Induction therapy				
Corticosteroids	64	6.05	1.07 (0.71-1.59)	0.76
Thymoglobulin	29	8.29	1.57 (1.02-2.41)	0.04
IL-2 receptor antagonist	22	7.17	1.27 (0.79-2.04)	0.31
Muromonab-CD3	4	4.63	0.77 (0.29-2.11)	0.62
Alemtuzumab	3	5.41	0.91 (0.29-2.88)	0.88
Maintenance therapy[c]				
Cyclosporine	42	6.31	1.12 (0.75-1.66)	0.59
Tacrolimus	51	5.67	0.92 (0.63-1.36)	0.68
Azathioprine	24	7.28	1.30 (0.83-2.06)	0.25
Mycophenolate mofetil	62	6.19	1.13 (0.76-1.68)	0.56

© 2020 American Medical Association. All rights reserved.

Mammalian target of rapamycin inhibitor	7	6.60	1.13 (0.52-2.43)	0.76
Corticosteroids	88	6.00	1.12 (0.64-1.97)	0.69
Human leukocyte antigen mismatch				0.90[b]
0	4	3.62	Reference	
1	8	12.5	3.45 (1.04-11.4)	
2	10	7.29	2.01 (0.63-6.42)	
3	15	5.53	1.53 (0.51-4.60)	
4	17	5.26	1.45 (0.49-4.31)	
5	26	6.96	1.92 (0.67-5.51)	
6	13	6.42	1.77 (0.58-5.44)	
Unknown	9	3.68	1.02 (0.31-3.30)	
Post-transplant diagnosis cutaneous squamous cell carcinoma[d]				<0.001
No	83	4.89	Reference	
Yes	19	65.6	13.4 (8.16-22.1)	
Post-transplant diagnosis of cutaneous basal cell carcinoma[d]				<0.001
No	93	5.45	Reference	
Yes	9	39.8	7.30 (3.68-14.5)	
Ambient ultraviolet B radiation				0.04[b]
Quartile 1	34	7.98	Reference	
Quartile 2	24	5.45	0.68 (0.40-1.15)	
Quartile 3	26	6.04	0.76 (0.45-1.26)	
Quartile 4	18	4.18	0.52 (0.30-0.93)	
Ambient ultraviolet A radiation				0.09[b]
Quartile 1	38	7.79	Reference	
Quartile 2	20	5.28	0.68 (0.39-1.16)	
Quartile 3	22	5.11	0.66 (0.39-1.11)	
Quartile 4	22	5.11	0.66 (0.39-1.11)	
Time since transplant, years[d]				<0.001[b]
0-1.9	10	1.88	Reference	
2-4.9	30	5.47	2.91 (1.42-5.95)	
5-9.9	35	7.62	4.05 (2.01-8.19)	
≥10	27	14.4	7.65 (3.71-15.8)	

CI = confidence interval, IRR = incidence rate ratio.

[a] For each induction and maintenance immunosuppressive drug, the reference group is unexposed patients. Global p-values are reported for each characteristic unless specified otherwise.

[b] P-value for trend

[c] Refers to medication prescriptions received at the time of transplant

[d] Post-transplant diagnoses of cutaneous squamous cell carcinoma and basal cell carcinoma, and time since transplant, were treated as time-dependent risk factors

© 2020 American Medical Association. All rights reserved.